Awesome viddeo explaining the way in which the antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein that is only expressed on the surface of myeloma cells. This initiates antibody-dependent cellular cytotoxicity activity that kills myeloma cells and leaves healthy cells i...

Lior Carmon, Vaxil Biotherapeutics Ltd., Nes-Ziona, Israel
Phase I/II study of Immucin, a pan-HLA, anti-MUC1 signal peptide vaccine in MM patients with residual disease or progression following autologous stem cell transplant.